PLANET MICROCAP TORONTO POWERED BY MICROCAPCLUB - ELECTROCORE INC

Explicit Guidance:

• Adjusted EBITDA: Targeting a return to adjusted EBITDA positivity in the back half of 2027.
• Sales & Marketing Efficiency: Goal to reduce sales and marketing expenses as a percentage of revenue from ~60% (2024 levels) to the industry norm of 40–50%.
• Debt Amortization: Existing $7.5 million debt on the books will begin amortization in March 2027.
• Valuation Context: Management notes the stock currently trades at 1.9–2.0x forward revenue, compared to a 10-year sector mean of ~4.5x.
• Growth Reference: Historical compound annual growth rate (CAGR) of ~50% over the last five years (used as a benchmark for potential future scaling).

Business-Segment Outlook:

• VA Commercial Expansion: Expecting to "make a significant dent" in the VA market over the next two years by penetrating the remaining ~67% of the 600,000 headache patient population and adding the Quell Fibromyalgia product to the sales mix.
• Quell Fibromyalgia Pipeline: Anticipating massive growth potential; currently selling to only ~30% of existing VA accounts, leaving ~70% of the market untapped. Specifically targeting the 8–11% of active duty military personnel returning from deployment with fibromyalgia.
• CIPN Indication (Quell): Filed FDA 510K for Chemotherapy-Induced Peripheral Neuropathy (CIPN) with "breakthrough designation"; currently the only product in the pipeline with this specific FDA pathway for this indication.
• TACSTIM (Tactical Stimulation): Leveraging B2B contracts with the Air Force Research Labs and Defense Language Institute to expand into active-duty military cognitive enhancement and language acquisition markets via a general wellness classification to bypass prescription red tape.
• TruVega (DTC): Prioritizing slower but more profitable growth in the direct-to-consumer general wellness segment (sleep, stress) rather than triple-digit acceleration to align with EBITDA goals.
• Commercial Diversification: Progressing on formulary/contract status with Kaiser Permanente (12.5M lives) to reduce reliance on the VA (9.5M lives).

Market and Competitive Outlook:

• Product Uniqueness: Identifying CIPN as a market with no current medical or pharmaceutical competitors, positioning the Quell device as the potential leading product.
• Technology Differentiation: Emphasizing systemic "buckshot" approach of vagus nerve stimulation (touching stomach, liver, spleen, brain) versus "sniper shot" pharmaceuticals, creating a competitive moat for multi-symptom patients.
• Market Size: Projecting a total addressable market (TAM) in the health/wellness space ranging from $101M to $5B depending on scope inclusion; highlighting the 600,000 VA headache patients and 9.5M VA covered lives for off-label PTSD usage.
• Patent Moat: Maintaining protection across 250 patents/patents pending, specifically covering cervical non-invasive vagal nerve stimulation (80–90% of vagal fibers) and mobile app control integration.

Macro / Industry Outlook:

• Federal Market Dynamics: Leveraging a new leadership team with 10–15 years of federal marketplace experience to navigate regulatory landscapes and expand into Federal Workers' Comp and TRICARE.
• Regulatory Strategy: Utilizing FDA "breakthrough designation" pathways to accelerate development and approval for new indications (CIPN, PTSD).
• Supply Chain/Capability: Developing ruggedized, military-spec hardware (TACSTIM) capable of surviving extreme conditions (tank runs, weapon use) to meet specific defense sector requirements.

Strategic Initiatives:

• Leadership Transition: Implemented new co-CEO structure (Joshua & Mike Fox) in April 2026; Fox brings specific expertise in commercializing devices for federal and military markets.
• M&A Integration: Fully integrating the Neurometrics acquisition (Quell Fibromyalgia) to expand the product portfolio beyond headaches, having already grown that specific segment ~30% sequentially post-acquisition.
• R&D Catalysts: Filing new indications (CIPN) and exploring multiple shots on net across 30+ investigator-initiated trials for indications including PTSD, mild TBI, gastroparesis, and stroke.
• Capital Allocation: Maintaining a "clean cap table" with no ratchets, anti-dilutes, or black shoal warrants; no active capital raising plans, focusing instead on organic growth and stock buybacks.

Risks and Headwinds to Outlook:

• VA Penetration Pace: The VA market is highly fragmented (1,700 budgeted locations, 1,300 writing sites); success depends on physical sales presence and introducing new products across accounts.
• Regulatory Uncertainty: Future growth relies on successful FDA approvals for new indications (CIPN) and maintaining general wellness classifications for military products to avoid prescription hurdles.
• Margin Dilution Risk: Potential for lower contribution margins if the DTC wellness business grows too aggressively without discipline, threatening the EBITDA positive timeline.
• Market Education: Need to educate the federal market on off-label uses (PTSD) and the systemic benefits of vagus nerve stimulation versus pharmaceutical alternatives.

Management Tone on the Future:

• Confidence Level: High confidence in the "turnaround" narrative and the scalability of the technology, citing a "very clean cap table" and experienced new leadership.
• Strategic Shift: Moving from an R&D-heavy phase to a commercial scaling phase, emphasizing "multiple shots on net" rather than reliance on a single product.
• Hedges: Explicitly stated that DTC growth will be controlled ("grow slower but more profitably") to ensure the 2027 EBITDA target is met, indicating a disciplined approach over aggressive top-line expansion.
• Valuation Sentiment: Management views the current market price as undervalued relative to historical sector multiples (1.9–2.0x vs 4.5x).

Miscellaneous:

• Stock Performance: Shares have appreciated ~71–72% year-to-date, with a high of ~182% improvement from the December 31st baseline.
• Insider Activity: Founder Dr. Tom Errico and board members continue to exercise warrants and invest in the company, signaling strong internal alignment.
• Corporate Structure: Ticker symbol: ECOR.